Summary & Overview
HCPCS J0120: Injection, Tetracycline, Up to 250 mg
HCPCS Level II code J0120 denotes the injectable administration of tetracycline up to 250 mg. As an HCPCS Level II drug code, it identifies a specific parenteral antibiotic product and the service of administering that medication. Nationally, accurate coding for injectable antimicrobials matters for clinical documentation, pharmacy inventory management, and payer adjudication.
Key payers covered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what the code denotes, typical sites where the service is delivered, and the clinical context for injectable tetracycline. The publication also summarizes payer coverage patterns and common billing considerations, presents benchmark metrics where available, and highlights recent policy clarifications relevant to HCPCS drug coding.
This summary provides clinicians, coders, and billing managers with the context needed to recognize when J0120 applies, understand payer relevance at a national level, and locate the operational and policy information included in the full publication. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J0120 represents an injection of tetracycline, up to 250 mg. This code covers the administration of a tetracycline antibiotic formulation delivered by injection. The service type is drug administration / injectable antibiotic therapy. The typical site of service for this injectable medication is outpatient clinical settings such as physician offices, outpatient infusion centers, ambulatory care clinics, and emergency departments.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient presents to an outpatient infusion clinic or primary care office for intramuscular antibiotic therapy for a bacterial infection where oral therapy is not appropriate or tolerated. Typical patients include adults or adolescents with cellulitis, acne requiring long-acting tetracycline injections, or pregnant patients when tetracycline is indicated by specialist oversight (rare). The procedure involves medication verification, informed consent, allergy check, site selection (usually deltoid or gluteal for intramuscular injection), aseptic preparation, administration of J0120 (tetracycline, up to 250 mg), monitoring for 15–30 minutes for immediate adverse reaction, documentation of lot number and dose, and scheduling follow-up or additional doses if clinically indicated. The typical site of service is an outpatient clinic, physician office, ambulatory infusion center, or emergency department when urgent intramuscular antibiotic is required.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier information | Rarely used; default when no other modifier applies |
22 |